The Need For Digital Networks To Support Cell And Gene Therapies

By Carla Reed, president, New Creed LLC Cell and gene therapies are game changers. Critical health conditions that were once chronic or terminal are now being addressed, which is exciting news for patients and caregivers. But these therapies have a level of complexity from a supply chain perspective that needs new approaches, including a high level […]

Does Blockchain Make Sense For The Cell & Gene Therapy Supply Chain?

By Carla Reed, president, New Creed LLC Life sciences companies engaged in the transition from clinical to commercial scale are challenged by the ability of current suppliers to meet the demand for materials and services as the volume of source ingredients is increased and production capacity and yield are stabilized. In the case of cell and […]

Recalibrating The Supply Chain For Allogeneic Cell Therapies

By Carla Reed, president, New Creed LLC In November 2018, I wrote an article about establishing a supply chain for autologous cell therapies — those formulated using a patient’s own cells. This partner piece highlights considerations that need to be taken into account when developing a commercialization and supply chain strategy for allogeneic cell therapies, in which cells […]

A cGDP Primer: New Distribution Models For Life Science Supply Chains

By Carla Reed, president, New Creed LLC The life sciences industry has undergone many changes over the last decade, with consolidation, mergers, and acquisitions across both small and large pharmaceutical and biotech companies. One result of these changes is complex supply chain models, with a combination of in-house and outsourced research, product development, and commercial […]

A Risk-Based Approach To Environmental Monitoring & Control For Pharmaceutical Distribution

By Carla Reed, president, New Creed LLC Over the past few decades, many companies have spent time and capital investment in assessing and mitigating risk factors across the extended supply chain. However, even for those companies that have designed and implemented state-of-the-art operational supply and logistics networks, there is always risk that products may be […]

Selecting Secondary Packaging For Bio/Pharma Products — What You Need To Know

By Carla Reed, president, New Creed LLC Once a small or large molecule product has passed the various hurdles in clinical trials, it faces important considerations related to market acceptance and commercialization. Irrespective of the nature or formulation of the product, there is always a heavy focus on the primary packaging element — the final […]

5 Proven Steps To Successfully Select & Onboard Outsourced Logistics Partners

By Carla Reed, president, New Creed LLC 5 Proven Steps To Successfully Select & Onboard Outsourced Logistics Partners In preceding articles in this series, we reviewed some of the challenges and remediation approaches for the storage and distribution of life science products, highlighting some of the specific risks related to storage, transportation, and material control […]